Search clinical trials for: AZD1775

Total 102 results

AstraZeneca

Completed

To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

Healthy

United Kingdom
AstraZeneca

Withdrawn

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

Healthy

United States
Dana-Farber Cancer Institute
AstraZeneca

Completed

CISPLATIN + AZD-1775 In Breast Cancer

Triple-negative Metastatic Breast Cancer

United States
AstraZeneca

Completed

To Study Safety, Tolerability and Pharmacokinetics of AZD1305 in Healthy Male Japanese Subjects

Healthy

Japan
AstraZeneca

Completed

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Refractory Solid Tumours | Relapsed Small Cell Lung Cancer (SCLC)

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal High Grade Serous Adenocarcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage IIIA Fallopian Tube Cancer AJCC v7 | Stage IIIA Ovarian Cancer AJCC v6 and v7 | Stage IIIA Primary Peritoneal... and other conditions

United States
AstraZeneca

Completed

AZD6765 Severe Major Depressive Disorder (MDD) IV

Major Depressive Disorder

United States
AstraZeneca

Completed

Single Ascending Dose Study (SAD) iv Formulation (2006-006253-27)

Healthy

Sweden
AstraZeneca

Completed

Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction

Left Ventricle Function

Sweden
AstraZeneca

Terminated

A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males

Healthy Subjects

United States
NYU Langone Health
AstraZeneca

Completed

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
AstraZeneca

Completed

A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock

Septic Shock | Severe Sepsis

Japan
Joseph Paul Eder
Dana-Farber Cancer Institute; The Cleveland Clinic; Vanderbilt-Ingram Cancer...

Terminated

OLAParib COmbinations (OLAPCO)

Cancer

United States
Samsung Medical Center

Completed

Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy

Advanced Gastric Adenocarcinoma

Korea, Republic of
UNC Lineberger Comprehensive Cancer Center
AstraZeneca

Completed

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Carcinoma, Squamous Cell of Head and Neck

United States
AstraZeneca

Completed

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States, South Africa, Chile, Slovakia
Ardelyx

Completed

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Healthy
AstraZeneca

Active, not recruiting

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Advanced Solid Tumours

United States
National Center for Complementary and Integrative...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaborators

Completed

Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment (SyNCH)

Chronic Hepatitis C

United States
AstraZeneca
Quintiles, Inc.

Completed

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Solid Tumors

United States, France, United Kingdom, Netherlands
National Cancer Institute (NCI)

Terminated

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1... and other conditions

United States
AstraZeneca

Active, not recruiting

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)

Muscle Invasive Bladder Cancer

Spain, United States, Canada, France, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute

Completed

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Lung Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Malignant Neoplasm in the Brain and other conditions

United States
Ardelyx

Completed

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Healthy Volunteers

United States
AstraZeneca

Completed

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

Advanced Solid Tumours

Korea, Republic of, Australia, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
AstraZeneca

Completed

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Spain, Poland, Hungary, Ukraine, Germany
Ardelyx

Completed

To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers

Healthy Volunteers

United States
National Cancer Institute (NCI)

Completed

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Glioblastoma | Gliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant

United States, Canada
Ardelyx

Completed

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

Hyperphosphatemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Ardelyx
AstraZeneca

Completed

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

Healthy

United States
Ardelyx
AstraZeneca

Completed

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

Healthy

United States
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Ovarian Undifferentiated Carcinoma | Ovarian... and other conditions

United States, Canada, Singapore
AstraZeneca

Completed

An Interaction Study With Digoxin and AZD1305

Atrial Fibrillation

Sweden
National Cancer Institute (NCI)

Terminated

Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Metastatic Squamous Cell Carcinoma in... and other conditions

Canada
University of Washington
National Cancer Institute (NCI)

Completed

WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Pineoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Rhabdomyosarcoma | Refractory Medulloblastoma | Refractory Neuroblastoma | Refractory Rhabdomyosarcoma | Central Nervous System Embryonal Tumor With... and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome With Isolated Del(5q)

United States
AstraZeneca

Completed

A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

Healthy

United States
AstraZeneca
University of Oxford; University of Manchester

Completed

Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects

Depression

United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

Glioblastoma | Recurrent Glioblastoma

United States
AstraZeneca

Terminated

A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765 (AZD6765 EEG)

Healthy

France
National Cancer Institute (NCI)

Withdrawn

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Recurrent Childhood Acute Myeloid Leukemia | CNS 2a | CNS 2b | CNS 2c | CNS1
AstraZeneca
Quintiles, Inc.

Completed

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

Solid Tumours

United States
AstraZeneca

Completed

An Interaction Study of Ketoconazole/Verapamil Versus AZD1305

Healthy

Germany
National Cancer Institute (NCI)

Terminated

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Stage I Uterine Corpus Cancer AJCC v7 | Stage IA Uterine Corpus Cancer AJCC v7 | Stage IB Uterine Corpus Cancer AJCC v7 | Stage II Uterine Corpus Cancer AJCC v7 | Cervical Carcinoma | Stage IB2 Cervical Cancer AJCC v6 and v7 | Stage II Cervical Cancer AJCC v7 | Stage II Vaginal Cancer AJCC v6 and v7 and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Advanced Malignant Solid Neoplasm

United States

Search clinical trials for: AZD1775

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations